Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Leukemia 45Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Burkitt Lymphoma 12Leukemia, Biphenotypic, Acute 9Recurrence 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, T-Cell 4Leukemia, Myeloid, Acute 3Neoplasms 2Neoplasm, Residual 2Lymphoma, T-Cell 2Down Syndrome 2Mucositis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Immunoproliferative Disorders 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

fludarabine phosphate 4fludarabine 4Cyclophosphamide 4blinatumomab 3ponatinib 2ibrutinib 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2Bone Marrow Transplantation 2AP 1903 reagent 2pegaspargase 1durvalumab 1asparaginase erwinia chrysanthemi recombinant 1Rituximab 1Pharmacogenomic Testing 1Methotrexate 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Dexamethasone 1Daunorubicin 1CLR1404 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoproliferative Disorders × pegaspargase × Other hematologic neoplasm × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡